Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials

BACKGROUND: The histamine H3 receptor has emerged as one of the most promising targets of novel pharmacotherapy for narcolepsy. Studies now aim to investigate the optimal dose of enerisant, a novel H3 antagonist/inverse agonist, for the treatment of excessive daytime sleepiness in patients with narc...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Yuichi, Uchiyama, Makoto, Umeuchi, Hideo, Onishi, Koichi, Ogo, Hiroki, Kitajima, Iwao, Matsushita, Isao, Nishino, Izumi, Uchimura, Naohisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862520/
https://www.ncbi.nlm.nih.gov/pubmed/35193545
http://dx.doi.org/10.1186/s12888-022-03785-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862520/
https://www.ncbi.nlm.nih.gov/pubmed/35193545
http://dx.doi.org/10.1186/s12888-022-03785-7

Ejemplares similares